LENZ Therapeutics, Inc. cotiza a 3.61 USD y tiene una capitalización bursátil de $113M. En los últimos 12 meses ha facturado $21M con un margen de flujo de caja libre del -366.7%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presb…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $-1.32 | $-1.16 |
| Estimado | $-0.94 | $-1.07 | $-1.07 | $-0.92 |
| Sorpresa | — | — | -23.4% | -26.1% |
| Métrica | LENZ | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 97.8% | 57.0% | +40.8% |
| Operating Margin | -477.5% | -38.6% | -438.8% |
| Net Margin | -430.3% | -33.6% | -396.7% |
| FCF Margin | -366.7% | -13.9% | -352.8% |
| ROE | -28.9% | -40.4% | +11.5% |
| ROA | -26.9% | -32.0% | +5.2% |
| Current Ratio | 14.23 | 2.84 | +11.39 |
| Debt / Equity | — | 0.28 | — |